Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
NeuroSense Therapeutics has entered a binding term sheet with a major global pharmaceutical company to advance PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). The agreement includes a substantial upfront payment, funding for Phase 3 trials, milestone payments, and double-digit royalties on sales. The pharmaceutical company will have exclusive rights to market and sell PrimeC in key territories, while NeuroSense retains rights in others. PrimeC, a combination of two FDA-approved drugs, has shown promising efficacy and safety in clinical trials, potentially offering a significant advancement in ALS treatment.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s disease. The company aims to create combined therapies targeting multiple disease pathways to address significant unmet medical needs.
YTD Price Performance: 74.36%
Average Trading Volume: 261,137
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $31.45M
See more insights into NRSN stock on TipRanks’ Stock Analysis page.
